Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 36%
Hold 29%
Sell 7%
Strong Sell 0%

Bulls say

Icon is well-positioned for long-term growth due to its strong data points, efficient business mix, and focus on late-stage clinical trials. However, potential ESG challenges and margin fluctuations may pose risks to the company's financial performance. Overall, with positive commercial momentum and potential for a rebound in margins, the outlook for Icon's stock is positive.

Bears say

Icon is a global contract research organization that has shown strong commitments to sustainability and environmental targets, leading to an above-average score from organizations like CDP and EcoVadis. However, the company has seen a decline in revenue and margins, with a projected adj. EBITDA margin of 16.5% and an estimated 4% organic revenue contraction in 2026 compared to 2025. Management has also indicated that they expect a similar progression throughout the rest of 2026 and that a significant amount of business is typically awarded in the days leading up to a quarter end. Additionally, the divestiture of Symphony Health and a new focus on targeted capital allocation and portfolio optimization may signal a shift in the company's strategic direction.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 36% recommend Buy, 29% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.